Kintara Therapeutics and TuHURA Biosciences announced the reopening of patient enrollment in Kineta's VISTA-101 clinical trial, with 30 out of 39 patients enrolled, and discussed a potential acquisition of Kineta's KVA12123 immunotherapy asset, which has shown promising initial results.